摘要
目的:比较EPOCH方案和CHOP方案一线治疗非特殊性外周T细胞淋巴瘤(PTCL-U)的疗效及不良反应。方法:A组:2008年1月至2010年4月,24例经病理确诊的PTCL-U患者,采用EPOCH方案化疗:足叶已甙50mg/(m2·d),长春新碱0.4mg/(m2·d),表阿霉素15mg/(m2·d),上述三种药物持续静脉滴注96h,环磷酰胺750mg/m2,静脉滴注,d5;强的松60mg/(m2·d),口服,d1-5。每3周为1周期。B组:2005年1月至2007年4月PTCL-U患者35例,采用CHOP方案化疗:环磷酰胺750mg/m2,静脉滴注,d1,表阿霉素75mg/m2,静脉滴注,d1,长春新碱1.4mg/m2,静脉滴注,d1,强的松60mg/(m2·d),口服,d1-5,每3周为1周期。对两组的近期疗效、疾病进展时间、不良反应进行分析比较。结果:A组和B组的完全缓解效率分别为66.7%(16/24)和40.0%(14/35),有显著性差异(P=0.0441),有效率分别为79.2%(19/24)和65.7%(23/35),无显著差异(P=0.2624)。A组和B组的中位疾病进展时间12.0月(1-27月)、10月(1-28月)(P=0.2045)。主要不良反应白细胞减少、神经毒性、脱发、心脏毒性等指标均无显著性差异(P>0.05)。轻度口腔炎的发生率A组高于B组:24.8%∶13%(P<0.05)。结论:一线治疗PTCL-U,EPOCH方案近期疗效较CHOP方案具有一定的优势,不良反应相近,耐受性好。
Objective：To compare the efficacy and toxicity of EPOCH regimen and CHOP regimen in the first line treatment for peripheral T cell lymphoma - unspecified （PTCL - U）. Methods：Group A： from January 2008 to April 2010,24 cases by pathological diagnosed of PTCL - U patients, using EPOCH regimen chemotherapy： etoposide 50mg/（ m^2 · d ）, vineristine 0.4mg/（m^2 · d）, epirubicine 15 mg/（ m^2 · d ）, the above three drugs continuous intravenous drip 96h, eyelophosphamide 750mg/m^2, iv, d5, prednisone 60rag/（ m^2 ·d） , po, d1-5; three weeks/cycle. B group：from January 2005 to April 2007,35 PTCL - U patients with CHOP scheme ehemotherapy：cyclophosphamide 750mg/m^2,iv, d1, epirubieine 75mg/m^2, iv, d1, vineristine 1.4mg/m^2, iv, d1, prednisone 60mg/（ m^2 · d）, po, d1-5 ; three weeks/cycle. The efficacy,time to disease progression（TTP） and toxicity of the two regimens were analyzed. Results：The complete remission efficiency （CR）of A and B group were 66.7% （16/24） and 40.0% （14/35） respectively,there was significant difference （P=0. 0441）. The response rates （RR） of A and B group were 79.2% （ 19/ 24） and 65.7~7o （23,/35） ,there was no significant difference （P=0.2624） .The median TTP was 12.0 months （1 - 27 months） in group A and 10.00 months（1 - 28 months） in group B （P= 0. 2045）. Major side effect of the two groups such as leukopenia, neurotoxieity, hair loss, cardiac toxicity had no significant differeree （P 〉 0.05 ）. Mild stomatitis was found 24.8% in group A and 13% in group B （P 〈 0.05）. Conclusion：To a certain extent, EPOCH regimen was superior to CHOP regimen in the first - line treatment for peripheral T - cell lymphomas - unspecified. There were similar major side effects and good tolerance.
出处
《现代肿瘤医学》
CAS
2014年第2期420-422,共3页
Journal of Modern Oncology
关键词
外周T细胞淋巴瘤
化学治疗
EPOCH方案
CHOP方案
药物持续静脉滴注
peripheral T - cell lymphomas - unspecified （ PTCL - U）
chemotherapy
EPOCH regimen
CHOP regimen
drug continuous intravenous drip
